Inclusion Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

- Zidovudine (AZT), didanosine (ddI), dideoxycytidine (ddC), erythropoietin (Eprex),
other agents granted Treatment IND or expanded access status.

- Investigational triazoles.

- Pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia (PCP).

Patients with the following are excluded:

- History of cerebral toxoplasmosis or toxoplasmosis infection in any other organ or
tissue.

- Focal neural abnormalities (except peripheral neuropathy) or mass lesions on a
previous computerized tomography (CT) scan or magnetic resonance image (MRI), unless
subsequent workup rules out toxoplasmosis, in which case abnormalities must have been
stable for at least 2 months.

- Known or suspected allergy or severe intolerance to study drugs.

Patients must have:

- Positive toxoplasma serology.

- HIV infection.

- Willingness and ability to comply with the protocol and capability of giving written
informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

- Current diagnosis of cerebral toxoplasmosis or toxoplasmosis infection in any other
organ or tissue.

- Known or suspected allergy or severe intolerance to study drugs.

Concurrent Medication:

Excluded:

- Anticoagulants. Other antifolates, sulfonamides, fansidar, macrolides,
5-fluorouracil, dapsone, or any other agent with known activity against Toxoplasma
gondii.